P. Laplaige

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Ondansetron Compared with Granisetron in the Prophylaxis of Cyclophosphamide-lnduced Emesis in Out-Patients: A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group Study

Alistair W. Stewart, B. McQuade, J.D.E. Cronje et al. · Oncology · 2009 · 56 citations

Medicine, Pharmacology, Pharmacotherapy +17

5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. final results of a randomised trial in metastatic colorectal cancer

P Rougier, B Paillot, A. Laplanche et al. · European Journal of Cancer · 1997 · 50 citations

Medicine, Oncology, Pharmacology +17

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Thomas Aparicio, Michel Ducreux, Roger Faroux et al. · European Journal of Cancer · 2018 · 46 citations · Full text

Medicine, Nutrition, Oncology +9

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study

Pascal Piedbois, D. Serin, Franck Priou et al. · Annals of Oncology · 2006 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17